The predictive value of 18F-FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy
- PMID: 25687534
- DOI: 10.1007/s00259-014-2820-9
The predictive value of 18F-FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy
Abstract
Purpose: To evaluate whether metabolic changes in the primary tumour during and after preoperative radiochemotherapy (RCT) can predict the histopathological response in patients with locally advanced rectal cancer as well as disease-free survival (DFS) and overall survival (OS).
Methods: Consecutive patients with cT2-4 N0-2 rectal adenocarcinoma were included. (18)F-FDG PET/CT was performed at baseline, at the end of the second week of RCT (early PET/CT) and before surgery (late PET/CT). The PET/CT results were compared with histopathological data (ypT0 N0 vs. ypT1-4 N0-2 as well as TRG1 vs.TRG2-5) and survival.
Results: The study included 126 patients. Among 124 patients in whom TNM classification was available, 28 (22.6 %) were ypT0 N0, and among all 126 patients, 31 (24.6 %) were TRG1. The areas under the curve of the early response index (RI) for identifying non-complete pathological response (non-cPR) were 0.74 (95 % CI 0.61 - 0.87) for ypT1-4 N0-2 patients and 0.75 (95 % CI 0.62 - 0.88) for TRG2-5 patients. The optimal cut-off for differentiating patients with non-cPR and cPR was found to be a reduction of 61.2 % (83.1 % sensitivity and 65 % specificity in ypT1-4 N0-2 patients; 85.4 % sensitivity and 65.2 % specificity in TRG2-5 patients). The optimal cut-off for late RI could not be found. The qualitative analysis of images obtained after RCT demonstrated 81.5 % sensitivity and 61.3 % specificity in predicting TRG2-5. After a median follow-up of 68 months, the low number of patients with local/distant recurrence or who had died did not allow the value of PET/CT for predicting DFS and OS to be calculated.
Conclusion: The early assessment of response to RCT by (18)F-FDG PET/CT can predict non-cPR allowing practical modification of preoperative treatment. Conversely, late RI is not sufficiently accurate for guiding the decision as to whether local excision or even observation is appropriate in an individual patient. Qualitative analysis of late PET/CT images is also not sensitive enough alone to rule out the presence of residual disease.
Similar articles
-
18F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival After Preoperative Radiochemotherapy with Bevacizumab in High-Risk Locally Advanced Rectal Cancer.J Nucl Med. 2019 Nov;60(11):1560-1568. doi: 10.2967/jnumed.118.222604. Epub 2019 Mar 15. J Nucl Med. 2019. PMID: 30877175 Free PMC article. Clinical Trial.
-
Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy.Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1583-93. doi: 10.1007/s00259-007-0426-1. Epub 2007 May 15. Eur J Nucl Med Mol Imaging. 2007. PMID: 17503039 Clinical Trial.
-
The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.Am J Clin Oncol. 2012 Aug;35(4):340-4. doi: 10.1097/COC.0b013e3182118e7d. Am J Clin Oncol. 2012. PMID: 21422901
-
Early prediction of response by ¹⁸F-FDG PET/CT during preoperative therapy in locally advanced rectal cancer: a systematic review.Eur J Surg Oncol. 2014 Oct;40(10):1186-94. doi: 10.1016/j.ejso.2014.06.005. Epub 2014 Jul 2. Eur J Surg Oncol. 2014. PMID: 25060221
-
F-18 FDG PET/CT in rectal carcinoma: where are we now?Clin Nucl Med. 2011 Oct;36(10):884-8. doi: 10.1097/RLU.0b013e318219b507. Clin Nucl Med. 2011. PMID: 21892038 Review.
Cited by
-
Does baseline [18F] FDG-PET/CT correlate with tumor staging, response after neoadjuvant chemoradiotherapy, and prognosis in patients with rectal cancer?Radiat Oncol. 2018 Oct 25;13(1):211. doi: 10.1186/s13014-018-1154-3. Radiat Oncol. 2018. PMID: 30359275 Free PMC article.
-
18F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival After Preoperative Radiochemotherapy with Bevacizumab in High-Risk Locally Advanced Rectal Cancer.J Nucl Med. 2019 Nov;60(11):1560-1568. doi: 10.2967/jnumed.118.222604. Epub 2019 Mar 15. J Nucl Med. 2019. PMID: 30877175 Free PMC article. Clinical Trial.
-
Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer.Cancer Res Treat. 2020 Apr;52(2):446-454. doi: 10.4143/crt.2019.261. Epub 2019 Sep 25. Cancer Res Treat. 2020. PMID: 31588705 Free PMC article.
-
Role of 18F-PET-CT to predict pathological response after neoadjuvant treatment of rectal cancer.Discov Oncol. 2021 May 18;12(1):16. doi: 10.1007/s12672-021-00405-w. Discov Oncol. 2021. PMID: 35201442 Free PMC article.
-
Magnetic Resonance Imaging Evaluation in Neoadjuvant Therapy of Locally Advanced Rectal Cancer: A Systematic Review.Radiol Oncol. 2017 Aug 16;51(3):252-262. doi: 10.1515/raon-2017-0032. eCollection 2017 Sep. Radiol Oncol. 2017. PMID: 28959161 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical